Brand Ozempic vs Compounded Semaglutide: Cost, Quality, and Differences

Why Compounded Semaglutide Exists

Semaglutide became available in two brand-name formulations: Ozempic® (for type 2 diabetes) and Wegovy® (for weight management). Both are manufactured by Novo Nordisk and have faced severe supply shortages since 2022 as demand skyrocketed.

When a drug appears on the FDA's drug shortage list, federal law permits state-licensed compounding pharmacies to prepare customized versions of that drug. This is why compounded semaglutide became legal and widely available — and why it has become the primary access point for many patients.

What Is Pharmaceutical Compounding?

Pharmaceutical compounding is the process of creating a customized medication from active pharmaceutical ingredients (API). Compounded semaglutide contains the same active ingredient (semaglutide) as brand-name products but is produced by a compounding pharmacy rather than Novo Nordisk.

Cost: The Stark Reality

Wegovy® costs $1,300-$1,600/month without insurance. Ozempic® costs $900-$1,200/month. Compounded semaglutide through a telehealth provider like AvataCore costs $150-$350/month — a savings of over $1,000 per month for most patients. See AvataCore pricing →

Quality and Safety: What to Know

FDA Oversight of Compounding Pharmacies

Not all compounding pharmacies are equal. The key distinction is between 503A and 503B facilities. 503B outsourcing facilities are subject to FDA inspection and Current Good Manufacturing Practice (CGMP) standards — the same standards applied to traditional drug manufacturers. Reputable telehealth providers partner exclusively with FDA-registered 503B compounding pharmacies.

What to Ask Before Ordering

• Is the pharmacy a 503B FDA-registered outsourcing facility?
• Is the active pharmaceutical ingredient sourced from an FDA-inspected manufacturer?
• Are certificates of analysis (COAs) available for each batch?
• Is the medication produced under sterile conditions?

Are There Any Differences in the Drug Itself?

The active ingredient — semaglutide — is the same. However, compounded versions may differ in formulation (some add vitamin B12), concentration, and excipients (inactive ingredients).

Regulatory Landscape

In early 2025, the FDA removed semaglutide from its shortage list, triggering a period of regulatory change. Compounded semaglutide remains available through many licensed providers as of 2026. Working with an established telehealth provider ensures you always have the most current guidance.